Content by Horizon Discovery

Batavia Biosciences and Immutep utilize Horizon’s GS knockout CHO K1 cell line expression system to generate high yielding cell line for LAG-3 immunotherapy

- Special licensing terms enable rapid access to CHOSOURCE platform to streamline SARS-CoV-2 therapeutic development and production processes - Supports global efforts to develop therapeutics, diagnostic assay components and vaccines to combat the COVID-19 Coronavirus pandemic

Micro-RNA compound found suitable for further development following favorable pharmacokinetic and pharmacodynamic study results

New arrayed B cell CRISPR knockout screening service strengthens support for development of therapeutics for diseases involving the immune system                    ·         First in the market, this unique service complements the Company’s T cell screening service ­

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to include ex vivo T lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

Horizon Discovery (LSE: HZD) (“Horizon” or the “Company”), a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announced the introduction of Edit-R™ CRISPRa arrayed crRNA (CRISPR RNA) libraries, the latest addition to its CRISPR activation (CRISPRa) reagent platform from the recently acquired Dharmacon™ business. 

The 5-Fusion Multiplex FFPE RNA Reference Standard from Horizon Discovery is a highly-characterized, biologically-relevant quality control material used to assess the performance of targeted NGS, RT-PCR and RT-qPCR assays aimed at detecting gene fusions. 

Horizon Discovery (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announces the launch of its new cell line-derived epidermal growth factor receptor (EGFR) Multiplex cell-free DNA (cfDNA) Reference Standard.

Horizon commissioned Eagle Genomics to complete the high quality genome assembly and gold standard gene annotation of the data for the project using their cutting-edge technology in close collaboration with the Ensembl group at the European Bioinformatics Institute (EMBL-EBI).

Horizon’s reference standards supported an assay development and subsequent clinical trial

Three new contract wins contributing a value of more than $2 million in 2017 with potential for long-term alliance development